Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose escalation study of AZD2281 in Japanese patients with advanced solid tumors
jRCT2080220492Phase 1
- Sponsor
- AstraZeneca
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in Non-hematologic malignancy, sponsored by AstraZeneca. Primary endpoint: Safety and tolerability of AZD2281.
02
Drugs
olaparib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080220492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220492.